Navigation Links
Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells

MOUNTAIN VIEW, Calif., March 4 /PRNewswire/ -- The Healthcare practice at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the North American biopharmaceuticals market to be held on Thursday, March 5, 2009 at 10:00 a.m. PST.


The biopharmaceutical industry has witnessed healthy growth and is experiencing several notable trends, such as the increased use of contract manufacturing organizations and the targeting of biotechnology companies for mergers and acquisitions by pharmaceutical companies or other biotechnology companies. In addition, this industry faces issues that are immersed in heated debate, such as the approval pathway of biosimilars.

This briefing will benefit strategic planners, business development managers, research professionals, marketing managers, and those who are considering entering this dynamic market. Highlights of the briefing include an analysis of overall market trends, general market sizing, and a look at selected issues.

"One of the hot topics in the biopharmaceutical market is the ethical debate surrounding the research and use of embryonic stem cells," notes Frost & Sullivan Research Analyst Katheryn Symank. "This issue is immersed in both political and ethical controversy. Some argue that the use of human embryonic stem cells is unethical while others support their use because of the potential medical good to the population."

To participate, please email Stephanie Ochoa, Corporate Communications, at with the following information: your full name, title, company name, company telephone number, company email address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit


    Stephanie Ochoa
    Corporate Communications - North America
    P: 210.247.2421
    F: 210.348.1003

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
2. Pioneer(R) Surgical Technology, Inc. Wins Frost & Sullivans 2009 North American Orthopaedic Tissue Engineering Technology Innovation Award
3. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
4. Frost & Sullivan Forecasts Early Rebound: Strong Growth Ahead for Global Economy
5. Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma
6. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
7. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
8. Frost & Sullivan Commends Honeywell Enraf for Cutting-Edge Products and Post-Sales Support
9. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
10. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
11. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):